Boston Scientific to take full control of Nalu Medical in $533m chronic pain tech deal

Boston Scientific Corporation (NYSE: BSX) is set to take full ownership of Nalu Medical, Inc., a California-based innovator in wearable neurostimulation systems, through a $533 million cash acquisition of the equity it does not already own. Boston Scientific has been a strategic investor in Nalu since 2017, and this move marks its transition from partial stakeholder to sole owner, deepening its commitment to next-generation chronic pain therapies.

The deal brings Nalu’s battery-free, app-controlled peripheral nerve stimulation (PNS) system under Boston Scientific’s full control, expanding its footprint in the growing market for minimally invasive, non-opioid pain solutions. The transaction values Nalu Medical at $600 million on a 100% basis.

The acquisition reflects a broader strategic shift: as demand rises for minimally invasive, opioid-sparing treatments, major device makers are racing to offer compact, digitally integrated solutions that deliver both clinical efficacy and user convenience. Nalu’s smartphone-controlled system, which has shown strong outcomes in trials and real-world use, fits squarely into this trend. For Boston Scientific, the deal is not just about adding a product—it’s about owning a future-proof pain care ecosystem.

Set to close in the first half of 2026, the transaction marks Boston Scientific’s transition from strategic investor—dating back to 2017—to full owner, as it acquires the remaining equity in the California-based startup. The move positions the medtech giant to compete more aggressively across both spinal and peripheral nerve stimulation markets, amid rising competition from players like Abbott and Nevro.

What makes Nalu Medical’s system a game-changer in the chronic pain therapy landscape?

The Nalu Neurostimulation System introduces a paradigm shift in how chronic pain is managed. Designed as a battery-free, miniaturized implantable pulse generator, the system delivers targeted peripheral nerve stimulation using wireless power from a discreet, externally worn Therapy Disc. This disc is controlled via a smartphone app, allowing patients to manage their therapy settings with ease and autonomy.

This compact system targets pain originating from nerves in the shoulder, lower back, and knee—areas often resistant to conventional treatments. Nalu Medical’s device interrupts pain signals before they reach the brain, offering relief without the systemic side effects of pharmacologic therapies. Importantly, the absence of an internal battery eliminates the need for replacement surgeries and reduces procedural risk, which could boost long-term patient adherence.

The system’s engineering enables it to rival larger implantable devices in terms of stimulation capabilities, waveform options, and upgradeability, while offering patients the freedom to live with less hardware burden. For physicians and payers, this translates to fewer follow-up surgeries, lower long-term costs, and a streamlined care model for chronic pain.

What clinical outcomes have been demonstrated for the Nalu system in trials and real-world use?

Nalu Medical has built a strong clinical foundation for its technology. The U.S. Food and Drug Administration (FDA) cleared the device under the 510(k) pathway in 2019, opening the door for its use across multiple chronic pain indications. The platform’s performance was evaluated in two key randomized controlled trials: COMFORT and COMFORT 2.

In the original COMFORT study, 87% of patients reported greater than 50% pain reduction at 12 months, a compelling indicator of both efficacy and durability. The follow-up trial, COMFORT 2, showed that 79% of participants experienced an average pain relief of 64% at six months, reinforcing the system’s reliability across time and use cases.

These findings have been echoed by real-world outcomes from more than 2,000 patients, where 94% reported clinically meaningful improvement. This broad dataset strengthens the argument for Nalu’s scalability and suggests it can maintain performance across diverse care settings and patient populations. Analysts believe these numbers provide Boston Scientific with a robust evidence base to support reimbursement discussions and market expansion strategies.

How does this acquisition fit into Boston Scientific’s long-term neuromodulation roadmap?

Boston Scientific’s neuromodulation business already includes spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation platforms. However, the addition of Nalu Medical’s PNS device introduces a new axis of growth in areas that spinal-focused systems don’t always reach effectively. The acquisition gives Boston Scientific a comprehensive, multi-modality approach to non-opioid pain therapy.

Neuromodulation President Jim Cassidy emphasized that the Nalu platform complements the company’s existing technologies and helps serve patient populations with severe and intractable pain. The strategy is not just defensive—it’s expansionary. As healthcare systems transition toward value-based care and outpatient delivery models, the need for wireless, low-maintenance, durable pain interventions is growing rapidly.

For Boston Scientific, this transaction also signals a sharpening focus on intelligent, app-enabled medtech that gives patients more control while allowing physicians to deliver more precise and personalized care. From a portfolio standpoint, the company will now offer one of the most diversified pain therapy lines in the market.

What are the financial implications of the transaction and how will it affect Boston Scientific’s earnings?

The total deal value includes an upfront cash payment of approximately $533 million for the equity Boston Scientific does not already own. On a 100% equity basis, the acquisition is valued at $600 million, prior to final closing adjustments. The company expects to finalize the transaction in the first half of 2026, with integration to follow.

Financially, Nalu Medical is forecasted to generate over $60 million in sales in 2025, with anticipated revenue growth exceeding 25% year-over-year in 2026. On an adjusted EPS basis, the acquisition is projected to be immaterial in 2026, slightly accretive in 2027, and more accretive in the years that follow.

On a GAAP basis, however, the transaction is expected to be dilutive in the near term, primarily due to amortization and acquisition-related costs. Analysts have pointed out that this is not unusual for high-growth medtech M&A and view the long-term earnings potential as compelling. Institutional investors appear to be comfortable with the short-term earnings drag, given the upside in addressable market expansion and operating leverage.

How are investors and institutions interpreting Boston Scientific’s latest medtech acquisition in the context of long-term growth?

Boston Scientific shares have remained steady in the wake of the announcement, suggesting investor sentiment is aligned with the company’s strategic direction. The neuromodulation business remains a core growth lever for the medtech giant, and the Nalu acquisition signals an intent to lead, not follow, in the shift toward compact, user-friendly, digital-first pain devices.

Institutional sentiment remains constructive, with analysts pointing to the deal’s potential to enhance revenue quality and margin mix over time. Boston Scientific’s ability to integrate innovative platforms and scale them commercially is seen as a competitive advantage, particularly in a neuromodulation sector that is still fragmented and ripe for consolidation.

The company’s past performance in absorbing innovative acquisitions—such as its buyout of Cosman Medical and BTG—suggests that it has the commercial infrastructure and R&D capabilities to take the Nalu platform global. As market dynamics evolve, especially in outpatient and ambulatory surgical settings, Boston Scientific is positioning itself to own the full care continuum for chronic pain.

What broader trends are driving consolidation and innovation in neuromodulation and pain therapy?

The global neuromodulation market is experiencing a transformation, driven by a convergence of clinical, technological, and policy trends. Rising chronic pain diagnoses, declining enthusiasm for pharmacologic interventions, and improved reimbursement frameworks for non-invasive therapies are reshaping how pain is treated across the care spectrum.

Peripheral nerve stimulation is emerging as a high-growth segment, offering a viable and often more targeted alternative to spinal cord stimulation. The advent of wearable and wirelessly powered devices like Nalu’s aligns with macro trends in digital health and patient-centric design. As clinical evidence mounts and payer systems evolve, analysts expect broader adoption of such technologies across U.S., European, and select Asia-Pacific markets.

The Boston Scientific–Nalu transaction may also catalyze further M&A activity in the space, as larger players seek to diversify portfolios with low-profile, high-impact solutions that blend engineering innovation with clinical depth. If the Nalu Medical integration proves successful, Boston Scientific could find itself at the center of the next wave in medtech’s evolution toward intelligent, minimally invasive care.

What are the key takeaways from Boston Scientific’s acquisition of Nalu Medical?

• Boston Scientific will move from strategic investor to full owner of Nalu Medical through a $533 million cash acquisition of the remaining equity it does not already hold.

• The transaction reflects a total valuation of $600 million on a 100% basis, with deal closure expected in the first half of 2026, pending regulatory approvals.

• The acquisition strengthens Boston Scientific’s neuromodulation portfolio by adding a battery-free, wearable peripheral nerve stimulation system, targeting opioid-free chronic pain management.

• Nalu’s device has shown high clinical efficacy, with 87% of patients in one trial reporting >50% pain reduction at 12 months, and 94% of real-world users achieving meaningful outcomes.

• Nalu is projected to generate over $60 million in sales in 2025, with 25%+ growth expected in 2026. The transaction is seen as EPS-accretive from 2027 onward.

• The deal is part of Boston Scientific’s strategy to expand its presence in the growing PNS market, leveraging its infrastructure to scale Nalu globally across outpatient and ambulatory care settings.